louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02374125: Teres Major Muscle and Subacromial Impingement Syndrome
Official title: Effectiveness of Teres Major Muscle Specific Treatment in Patients Diagnosed With Subacromial Impingement Syndrome
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Trigger Points in Teres Major Muscle
Subacromial Impingement Syndrome
Lead sponsor: Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Sponsor class: OTHER
First posted: 2015-02-27
Enrollment: 96
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: There is not a clear understanding of the origin of symptoms perceived by patients with impingement of the soft tissue structures of the subacromial space. Tendinopathy, tendon rupture or other pathologies, are present in asymptomatic subjects and subjects with symptoms and structural integrity can also be found.

Patients diagnosed with subacromial impingement syndrome frequently have myofascial trigger points in the teres major muscle. Travell and Simons reported that the symptoms caused by trigger points in this muscle are similar to those experienced by patients diagnosed with impingement syndrome, but a literature search provides few results regarding relationship between subacromial impingement syndrome and presence of myofascial trigger points in the teres major muscle.

This study aims to provide evidence of the results that can be obtained with a specific approach of teres mayor muscle by two manual techniques, Trigger Point Pressure Release and Diacutaneous Fibrolysis, in subjects with subacromial impingement syndrome, a condition that still representing both a diagnostic and therapeutic challenge. Secondary objective is to compare the outcomes between both techniques to select for each patient the most appropriate to their needs and characteristics.


Eligibility criteria: Inclusion Criteria:

* Age 18 years and over
* Clinical diagnosis of Subacromial Impingement Syndrome.
* Detectable trigger points in teres major muscle.
* Sign informed consent form.

Exclusion Criteria:

* Diacutaneous Fibrolysis contraindications
* Previous shoulder surgery (\<1year)
* Language barriers or cognitive issues that limit their ability to provide informed consent and participate in research.
* Patients with a pending litigation or court claim.

Primary outcomes:
measure: Change in Pain intensity (Using a VAS)
timeFrame: Change from baseline to 3 weeks.
measure: Change in Functional capacity (Abbreviated Constant-Murley score)
timeFrame: Change from baseline to 3 weeks.
Secondary outcomes:
measure: Change in Active Range of Motion
timeFrame: Change from baseline to 3 weeks.
measure: Patient perception of change (Global Rating of Change scale)
timeFrame: 3 weeks after recruitment
Other outcomes:
Locations:
city: Cornellà de Llobregat
country: Spain
facility: Catalan Health Institut. Sant Ildefons Rehabilitation Service
state: Barcelona
Study officials:
affiliation: IDIAP JORDI GOL
name: Martín Barra
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06252025: Immersive VR Reminiscence System for Facilitating Memory Retrieval Among Nursing Home Older Adults
Official title: The Effect of an Immersive VR Reminiscence System for Facilitating Memory Retrieval Among Nursing Home Older Adults
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Memory, Repressed
Emotional Regulation
Old Age
Keywords: Virtual Reality
Reminiscence Therapy
Lead sponsor: Shanghai Jiao Tong University School of Medicine
Sponsor class: OTHER
First posted: 2024-02-09
Enrollment: 36
Sex: ALL
Minimum age (years): 60
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: A VR game "Memo-gration" was designed to assist elderly people in reminiscence therapy. The ultimate scene design was crafted in a vintage Chinese aesthetic reminiscent of the previous century.

Detailed description: This study tailored a variety of instructional material within each virtual scenario, taking into account various memory triggers. Guidance is activated when the user is identified as making physical contact with an object or discussing a specific keyword. This encompasses textual assistance provided within the virtual environment, the display of multimedia information, and the provision of organized voice guidance. Following the system's instructions, users engaged in discussion with the caregiver, and had the freedom to terminate the conversation at their discretion and explore other topics by interacting with different items.

Eligibility criteria: Inclusion Criteria:

* (i) absence of significant cognitive impairment, visual impairment, hearing impairment, and communication ability.
* (ii) Obtained the pre-test and watched the film while wearing a VR headgear without experiencing any notable discomfort.

Exclusion Criteria:

* (i) Older adults with cognitive impairments that prevent normal communication
* (ii) Visually impaired

Primary outcomes:
measure: Profile of Mood States (POMS)
timeFrame: baseline and 1 day (study completion)
Secondary outcomes:
measure: Questionnaire on VR Experience
timeFrame: 1 day (study completion)
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Dian Zhu
state: Shanghai
Study officials:
affiliation: Shanghai Jiao Tong University School of Medicine
name: Dian Zhu, Dr
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06487325: A Clinical Study of Ultrasound-derived Fat Fraction to Assess Metabolic Dysfunction-Associated Steatotic Liver Disease
Official title: Clinical Study of Ultrasound-derived Fat Fraction to Assess Metabolic Dysfunction-Associated Steatotic Liver Disease in Obese Population
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Fatty Liver Disease
Lead sponsor: Qianfoshan Hospital
Sponsor class: OTHER
First posted: 2024-07-05
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Obese individuals, who were found to have fatty liver by B-mode ultrasound and underwent UDFF measurement, along with liver biopsy results, were retrospectively selected from The First Affiliated Hospital of Shandong First Medical University

Brief summary: Aims: To evaluate the diagnostic performance of ultrasound-derived fat fraction (UDFF) in assessing the degree of hepatic steatosis in an obese population, with liver biopsy as reference standard.

Materials and methods: Obese individuals, who were found to have fatty liver by B-mode ultrasound and underwent UDFF measurement, along with liver biopsy results, were retrospectively selected from The First Affiliated Hospital of Shandong First Medical University.The inclusion criteria were as follows: (1) BMI over 30 kg/m²; (2) diffuse fatty liver or inhomogeneous fatty liver diagnosed by conventional B-mode ultrasound; (3) serologic test results were available. The exclusion criteria include: (1) patients who have undergone liver resection or have liver space-occupying lesions; (2) pregnant women; (3) patients with incomplete medical history data.


Eligibility criteria: Inclusion Criteria:

* BMI over 30 kg/m²
* diffuse fatty liver or inhomogeneous fatty liver diagnosed by conventional B-mode ultrasound
* serologic test results were available

Exclusion Criteria:

* patients who have undergone liver resection or have liver space-occupying lesions
* pregnant women
* patients with incomplete medical history data

Primary outcomes:
measure: UDFF values
timeFrame: up to 1 year
Secondary outcomes:
measure: SWE values
timeFrame: up to 1 year
Other outcomes:
Locations:
city: Jinan
country: China
facility: QianfoshanH
state: Shandong
Study officials:
References:
Clinical trial NCT03103425: Evaluation of StatNet Device for Electroencephalogram (EEG) Recordings
Official title: Evaluation of StatNet Device for EEG Recordings
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Epilepsy
Seizures
Keywords: New onset seizures
Lead sponsor: Beth Israel Deaconess Medical Center
Sponsor class: OTHER
Collaborators: name: HydroDot, Inc.
First posted: 2017-04-06
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Outpatients Inpatients

Brief summary: The purpose of the study is to develop an emergency electroencephalogram (EEG) device, StatNet, that can be placed quickly by minimally-trained personnel and interpreted remotely for rapid identification of seizures.


Eligibility criteria: Inclusion Criteria:

* Adults \> age 18
* Epileptiform discharges present on routine EEG

Exclusion Criteria:

* Open head wounds
* Medically Unstable

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Boston
country: United States
facility: Beth Israel Deaconess Medical Center
state: Massachusetts
Study officials:
References:
Clinical trial NCT06411925: The Efficacy and Safety of Atock Dry Syrup With Acute Bronchitis Patients
Official title: A Multi-center, Randomized, Double-blinded, Active-controlled, Superiority, Phase 4 Trial to Evaluate the Efficacy and Safety of Atock Dry Syrup Sama With Acute Bronchitis Patients
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE4
Conditions: Acute Bronchitis
Lead sponsor: SamA Pharmaceutical Co., Ltd
Sponsor class: INDUSTRY
First posted: 2024-05-13
Enrollment: 260
Sex: ALL
Minimum age (years): 6
Maximum age (years): 11
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Clinical Study to Evaluate the Efficacy and Safety of Atock Dry Syrup with Acute bronchial Patients


Eligibility criteria: Inclusion Criteria:

1. Children aged ≥6 months to \<12 years old
2. Total Bronchitis Severity Scale excluding sputum(BSSEs) ≥4
3. Wheezing score ≥2
4. Subjects who present symptoms of Acute Bronchitis within 48 hours from screening visit

Exclusion Criteria:

1. Subjects with chronic respiratory diseases (e.g., asthma, COPD) or severe respiratory diseases (e.g., pneumonia, cystic fibrosis, influenza, active tuberculosis)
2. Subjects under treatment with corticosteroids, antibiotics medications
3. Subjects with severe hepatic and renal impairment
4. Subjects with a history of drug abuse
5. Subject with positive results in HbsAg or HCV Ab or HIV Ab tests at screening visit

Primary outcomes:
measure: The rate of subjects whose symptoms improved based on the wheezing score at 3 days
timeFrame: 3 days treatment period
Secondary outcomes:
measure: The rate of subjects whose symptoms improved based on the wheezing score at 7 days
timeFrame: 7 days treatment period
measure: The rate of subjects whose wheezing score improved by two or more grades at 3 and 7 days
timeFrame: 3 and 7 days treatment period
measure: The change in bronchitis severity score excluding the sputum (BSSEs) at 3 and 7 days
timeFrame: 3 and 7 days treatment period
measure: The change in patient satisfaction scores for wheezing (VAS, Visual Analogue Scale) at 3 and 7 days
timeFrame: 3 and 7 days treatment period
measure: The change in patient satisfaction scores for cough (COAT, COugh Assessment Test) at 3 and 7 days
timeFrame: 3 and 7 days treatment period
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Soonchunhyang University Seoul Hospital
Study officials:
References:
Clinical trial NCT03161925: Chinese Liver Cancer Clinical Survey
Official title: Chinese Liver Cancer Clinical Survey
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Primary Liver Cancer
Lead sponsor: Beijing Insight Science & Technology Co. Ltd.
Sponsor class: OTHER
First posted: 2017-05-22
Enrollment: 5000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who had been diagnosed with PLC were chosen

Brief summary: In order to make better use of clinical resources of the real world, strengthen the standardization of PLC diagnosis and treatment, and constantly improve the academic level of liver cancer in China, we intends to launch "Chinese Liver Cancer clinical Survey" project in cancer specialized hospitals and large general hospitals and to explore the best clinical pathway of PLC multidisciplinary consultation.

Detailed description: Primary liver cancer (PLC) is one of the most common malignant tumors of digestive system and also a serious threat to the health and safety of Chinese people, and has caused serious economic burden to the country. Research purposes: To understand the clinical characteristics of patients with primary liver cancer (PLC) in China; To investigate the etiology and pathogenesis of PLC in China; To understand the current status of clinical treatment of PLC in China, and to analyze the gaps among these conditions and domestic treatment guidelines, industry consensus, the international treatment guidelines; To understand the different treatment options and its clinical outcomes, and to explore the best treatment options; To explore the best clinical pathway of PLC multidisciplinary consultation; To provide the basis for the development of clinical guidelines for PLC in China.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of PLC after January 1,2012;
* First treatment and efficacy evaluation.

Exclusion Criteria:

* Complicated with another primary malignant tumor and secondary liver cancer.

Primary outcomes:
measure: Overall survival
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01183325: Prospective Evaluation of the Proceed Ventral Patch With and Without Laparoscopic Evaluation
Official title: Multicentric Evaluation of the Proceed Ventral Patch for Umbilical and Small Primary Ventral Hernias Less Than 3cm Diameter With One Year Follow-up
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Umbilical Hernias
Ventral Hernias
Keywords: Umbilical and small ventral hernias less than 3cm diameter
Lead sponsor: University Hospital, Ghent
Sponsor class: OTHER
Collaborators: name: Johnson & Johnson
First posted: 2010-08-17
Enrollment: 160
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: For small (2-3cm) ventral and umbilical hernias the discussion for primary suture repair or the use of mesh continues.

About 5 years ago the Ventralex patch was introduced, which combines a layer of PTFE mesh with a small polypropylene mesh and includes a circular memory ring. Despite the elegance of using this patch, recent experience showed several drawbacks both in design and efficacy (3).

With the recent development of the Proceed Ventral Patch (PVP), new elements have been introduced to overcome some of these issues.

The aim of this study is to evaluate the efficacy of clinical placement of the PVP in the intra-abdominal position in the treatment of small ventral hernias.


Eligibility criteria: Inclusion Criteria:

* Adult patient
* Written informed consent
* Umbilical, primary ventral hernias smaller than 3cm diameter

Exclusion Criteria:

* Hernias larger than 3cm
* Recurrence
* Children
* Emergency cases
* Incisional hernias

Primary outcomes:
measure: Percentage of adequately placed patches
timeFrame: At T 0 days
Secondary outcomes:
measure: Perioperative morbidity rate
timeFrame: Within 30 days
measure: Pre- and postoperative pain
timeFrame: At T 0 day, T 30 days and T 1 year
measure: Number of patients needed a repositioning of the patch
timeFrame: At T 0 days
measure: Reasons for inadequate positioning
timeFrame: At T 0 days
measure: Number of repositioning necessary
timeFrame: At T 0 days
measure: Complication ratio
timeFrame: At 1 year
measure: Recurrence rate at 1 year
timeFrame: At 1 year
Other outcomes:
Locations:
city: Bonheiden
country: Belgium
facility: Imelda Hospital
city: Ghent
country: Belgium
facility: University Hospital Ghent
Study officials:
affiliation: University Hospital, Ghent
name: Frederik Berrevoet, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00220025: Narrowband UVB Light Therapy to Patients With Dark Skin Types Who Have 10% of Their Body Involved With Psoriasis Vulgaris.
Official title: A Study To Determine the Efficacy of Whole Body Narrowband UVB Phototherapy in People With Darker Skin Types
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Psoriasis Vulgaris
Lead sponsor: Rockefeller University
Sponsor class: OTHER
First posted: 2005-09-22
Enrollment: 70
Sex: ALL
Minimum age (years): 14
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study offers narrowband UVB light therapy to patients with both light and dark skin types who have 10% of their body involved with psoriasis vulgaris.

Detailed description: Two groups of patients, having 10% of their body surface area involved with psoriasis vulgaris, will receive narrowband phototherapy. One group will have skin type I-IV, or light skin and the second group will have dark skin, or type V-VI.

All patients will receive phototherapy, with narrowband UVB, three times a week for six weeks, or a total of 18 treatments. 6mm punch skin biopsies will be done prior to starting therapy and at the completion of the study. Clinical assessments and photography will be done parallel to the skin biopsies. Results (clinically and histologically) of both groups will be compared.

Eligibility criteria: Inclusion Criteria:

Patients must have stable psoriasis vulgaris, which covers at least 10% of their bodies, for at least six months. Patients can not have not been treated with narrowband UVB in the past, although other light therapies are acceptable (i.e. broadband UVB and PUVA). Patients are not allowed to receive other therapies for their psoriasis, internal and topical, while they are participating in the study. Patients may continue using non-medicated moisturizer.

-

Exclusion Criteria:

-

Primary outcomes:
measure: Clinical and histological improvement of psoriasis
timeFrame: beginning and end of treatment
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: Rockefeller University Hospital
state: New York
Study officials:
affiliation: Rockefeller University
name: James G. Krueger, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Johnson-Huang LM, Suarez-Farinas M, Sullivan-Whalen M, Gilleaudeau P, Krueger JG, Lowes MA. Effective narrow-band UVB radiation therapy suppresses the IL-23/IL-17 axis in normalized psoriasis plaques. J Invest Dermatol. 2010 Nov;130(11):2654-63. doi: 10.1038/jid.2010.166. Epub 2010 Jun 17.
Clinical trial NCT02484625: The Effect of Dairy and Non-Dairy Snacks on Food Intake, Subjective Appetite in Children
Official title: The Effect of Solid, Semi-Solid and Fluid Dairy Products on Short-Term Food Intake and Satiety in Children
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Food
Eating
Appetite
Keywords: Snacking
Food Intake
Satiety
Obesity
Lead sponsor: Mount Saint Vincent University
Sponsor class: OTHER
Collaborators: name: University of Toronto
First posted: 2015-06-29
Enrollment: 40
Sex: ALL
Minimum age (years): 9
Maximum age (years): 14
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Randomized crossover
Primary purpose: BASIC_SCIENCE

Brief summary: Dairy products have the potential to be healthy snack foods for children and are provided in a variety of food matrices. For instance, milk represents a fluid product, yogurt can be classified as a semi-solid food, and finally, cheese is the example of solid food. This experiment is aimed to examine the effect of dairy products with different food matrices on satiety and food intake in children. Dairy products will be compared with other non-dairy snacks popular among children including cookies and potato chips.


Eligibility criteria: Inclusion Criteria:

* Born at full-term within the normal weight range
* 9-14 year old

Exclusion Criteria:

* Food sensitivities or allergies,
* Dietary restrictions,
* Health, learning, emotional or behavioural problems
* Receiving medication

Primary outcomes:
measure: Food intake (grams and kcal) measured with a test meal
timeFrame: 120 min
measure: Subjective appetite measured with Visual Analogue Scales
timeFrame: 0-120 min
Secondary outcomes:
measure: Cortisol
timeFrame: 0-120 min
Other outcomes:
Locations:
city: Halifax
country: Canada
facility: Mount Saint Vincent University
state: Nova Scotia
Study officials:
affiliation: Mount Saint Vincent University
name: Bohdan L Luhovyy, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Gheller BJF, Li AC, Gheller ME, Armstrong T, Vandenboer E, Bellissimo N, Anini Y, Hamilton J, Nunes F, Mollard RC, Anderson GH, Luhovyy BL. The effect of dairy products and non-dairy snacks on food intake, subjective appetite and cortisol levels in children: a randomized control study. Appl Physiol Nutr Metab. 2021 Sep;46(9):1097-1104. doi: 10.1139/apnm-2020-0909. Epub 2021 Mar 16.
Clinical trial NCT05130125: Retrospective Cohort Observational Study to Evaluate the Effectiveness and Safety of Fresh or Frozen Embryo Transfer
Official title: Retrospective Cohort Observational Study to Evaluate the Effectiveness and Safety of Fresh or Frozen Embryo Transfer After Ovarian Hyperstimulation (Administration of rFSH or HP-hMG Alone or Co-administration of rFSH and HP-hMG)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Infertility, Female
Lead sponsor: LG Chem
Sponsor class: INDUSTRY
First posted: 2021-11-22
Enrollment: 1166
Sex: FEMALE
Minimum age (years): 19
Maximum age (years): 39
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: infertile female patients

Brief summary: A multicenter, retrospective cohort observational study to evaluate the effectiveness and safety of fresh or frozen embryo transfer after ovarian hyperstimulation (administration of rFSH or HP-hMG alone or co-administration of rFSH and HP-hMG)

Detailed description: A multicenter, retrospective cohort observational study to evaluate the effectiveness and safety of fresh or frozen embryo transfer after ovarian hyperstimulation (administration of rFSH or HP-hMG alone or co-administration of rFSH and HP-hMG) to infertile female patients undergoing assisted reproductive technology to controlled ovarian hyperstimulation

Eligibility criteria: Inclusion Criteria:

* First IVF-ET cycle patients

Exclusion Criteria:

Poor ovarian responder

- At least two of the following three features must be present: (i) Advanced maternal age (≥ 40 years) or any other risk factor for Poor ovarian response (POR); (ii) A previous POR (≤ 3 oocytes with a conventional stimulation protocol); (iii) An abnormal ovarian reserve test (i.e. AFC \< 5-7 follicles or AMH \< 0.5-1.1 ng/mL)

Primary outcomes:
measure: Number of Oocytes
timeFrame: average of 14 days
Secondary outcomes:
Other outcomes:
Locations:
city: Gyeonggi-do
country: Korea, Republic of
facility: CHA Fertility Hospital
Study officials:
affiliation: Cha medical center
name: Jieun Shin
role: PRINCIPAL_INVESTIGATOR
References: